In a surprise decision, the FDA has delayed a ruling on the approval of Eli Lilly’s highly anticipated once-daily investigational rheumatoid arthritis (RA) drug baricitinib, instead issuing a complete response letter (CRL) to Lilly and its partner Incyte asking for additional clinical data on dosing and safety concerns. Lilly and Incyte disagree with the FDA’s conclusions and said more discussion with the agency might help speed the resubmission of data for the drug.
Baricitinib is a Janus kinase inhibitor currently in clinical studies for its effect on inflammatory and autoimmune diseases. Baricitinib had generated a good deal of excitement after the February 2017 publication of a study published in The New England Journal of Medicine that showed baricitinib produced significant clinical improvements in RA symptoms compared with placebo and adalimumab (Humira) when combined with methotrexate for patients with inadequate responses to methotrexate alone. The study suggests baricitinib may be an effective oral alternative to adalimumab, which is an infusion.
“We are disappointed with this action,” the company said, remaining confident in the benefit/risk of baricitinib as a new treatment option for adults with moderate to severe RA.
Lilly and Incyte had submitted data on baricitinib to the FDA in January 2016, a majority of which was positive. The companies also submitted additional data from a long-term extension study that suggested the drug’s previously recorded positive effects could be maintained for at least 48 weeks. These positive data had led some analysts to project $1.8 billion in sales for baricitinib by 2022 if it had been approved.
The FDA had already extended its review period of baricitinib by 3 months. Analysts had expected the agency to approve the drug, especially after its European approval in February 2016.
The delay in approving baricitinib resulting from the FDA’s decision to issue a CRL will be good news, however, for Sanofi and Regeneron, whose interleukin-6 inhibitor sarilumab—another RA drug that is expected to potentially become a blockbuster—may be approved imminently by the FDA. The delay in baricitinib’s marketing also potentially benefits Pfizer’s RA drug tofacitinib citrate (Xeljanz), which was approved in 2016 but has not yet generated expected sales.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.